ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis

This article originally appeared here.
Share this content:
ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis
ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis

WEDNESDAY, Aug. 2, 2017 (HealthDay News) -- The biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of moderate-to-severe plaque psoriasis, according to a study published online July 28 in the British Journal of Dermatology.

Kim Papp, M.D., Ph.D., from Clinical Research and Probity Medical Research in Waterloo, Canada, and colleagues randomized 308 patients (1:1) to receive ABP 501 or adalimumab (40 mg) every two weeks for 16 weeks. At week 16, patients with at least 50 percent improvement from baseline in psoriasis area-and-severity index score (PASI) were eligible to continue to Week 52 (152 patients), whereas adalimumab patients were re-randomized (1:1) to continue adalimumab (79 patients) or undergo a single transition to ABP 501 (77 patients).

The researchers found that PASI percent improvements were similar across groups for weeks 16, 32, and 50 (range, 85.8 to 88.2 percent), with no significant differences across groups in percentages of PASI 50, 75, 90, and 100 responders. Similarly, changes in percent body surface area affected were similar across groups and timepoints. There were no new safety issues reported, with adverse events similar between the groups.

"ABP 501 and adalimumab have similar clinical efficacy, safety, and immunogenicity profiles over 52 weeks, including after single transition, in this patient population," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which manufactures ABP 501 and funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Mortality Estimates Favor Annual Mammography From Age 40

Mortality Estimates Favor Annual Mammography From Age 40

Researchers estimate thousands of U.S. lives would be saved each year if mammograms started at age 40

Anti-Vaccine Info in Pregnancy May Delay Infant Immunization

Anti-Vaccine Info in Pregnancy May Delay Infant Immunization

Even if pregnant women later hear better info from doctors, they may still wait on vaccines

Hours Worked Impacted by Kids for Female, Not Male Doctors

Hours Worked Impacted by Kids for Female, Not ...

Findings from a national sample of dual-physician couples

is free, fast, and customized just for you!

Already a member?

Sign In Now »